Covid Vaccine Pfizer October. “october is possible, because very few things in life are impossible.” Pfizer is working to diversify the sample of its phase 3 trial as.
Photo Credit William Stanwood Holmes, Sherlock holmes from www.pinterest.com
The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The company said it plans to apply for emergency use authorization by the second half of november, too. Pfizer and its collaborator biontech released early study results on nov.
Pfizer’s premarket trading rose after the announcement.
Pfizer’s leading competitors in the vaccine race, moderna and astrazeneca, have been more vague about timing, saying they expect something before the end of the year. Pfizer is working to diversify the sample of its phase 3 trial as. Pfizer’s covid vaccine on track for regulatory review in october: Pfizer, which has partnered with biontech on its coronavirus vaccine, has begun enrolling 30,000 people in its phase three vaccine trial but is looking to expand its enrollment to 44,000.
